medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2019, Number 1

<< Back Next >>

Ann Hepatol 2019; 18 (1)

Lysosomal Acid Lipase: Can it be a New Non-Invasive Serum Biomarker of Cryptogenic Liver Fibrosis and Cirrhosis?

Gravito-Soares M, Gravito-Soares E, Gomes D, Tomé L

Language: English
References: 28
Page: 78-88
PDF size: 263.45 Kb.


ABSTRACT

Introduction and aim. The association between lysosomal acid lipase (LAL) activity and liver steatosis or fibrosis is poorly studied. The aim of our study was to determine the predictive power of LAL for cryptogenic liver steatosis and cryptogenic significant fibrosis/ cirrhosis. Material and methods. Cross-sectional observational study of 101 adult patients with unexplained elevated liver enzymes/hepatomegaly with or without dyslipidemia submitted to the determination of LAL activity and LIPA gene (E8SJMC. 894G→A) mutation. Seventy-one patients underwent liver biopsy or FibroScan®. Patients with an identifiable liver dysfunction cause and well-stablished NAFLD/NASH risk factors were excluded. Predictors for liver steatosis, significant fibrosis (≥ F2) or cirrhosis (F4) were evaluated. Results. Liver steatosis and fibrosis were mainly assessed by liver biopsy (74.6%; n = 53). Steatosis was present in 62.0% (n = 44), significant fibrosis in 47.9% (n = 34) and cirrhosis in 39.4% (n = 28). The median LAL was 0.36 (0.21-0.46)nmol/spot/h (vs. 0.29 (0.20-0.47); p = 0.558) for liver steatosis, 0.22 (0.11-0.29) nmol/spot/h (vs. 0.40 (0.34-0.51); p ‹ 0.001) for significant fibrosis and 0.21 (0.11-0.27) nmol/spot/h (vs. 0.40 (0.32-0.52); p ‹ 0.001) for cirrhosis. No LIPA gene mutations were found. LAL activity was the strongest predictor of significant fibrosis (AUROC: 0.833; p ‹ 0.001) with a cut-off of 0.265 (sensitivity: 85.9%; specificity: 75.0%) and cirrhosis (AUROC: 0.859; p ‹ 0.001) with a cut-off of 0.235 (sensitivity: 86.2%; specificity: 75.0%), being higher than FIB4, GUCI or APRI. However, LAL activity was not associated with liver steatosis (AUROC: 0.536; p = 0.558). Conclusion. LAL activity can be considered a non-invasive new marker of cryptogenic liver fibrosis with higher accuracy than other known biomarkers. LAL activity ‹ 0.265 nmol/spot/h was strongly associated with cryptogenic significant fibrosis and ‹ 0.235 nmol/spot/h with cryptogenic cirrhosis. LAL activity was not associated with cryptogenic liver steatosis.


REFERENCES

  1. Clin JL, Pavlides M, Moolla A, Ryan JD. Non-invasive markers of liver fibrosis: adjuncts or alternatives to liver biopsy? Front Pharmacol 2016; 7: 159.

  2. Al-Ghamdi AS. Fibroscan: a noninvasive test of liver fibrosis assessment. Saudi J Gastroenterol 2007; 13: 147-9.

  3. Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, Kumar M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 2017; 66: 1022-30.

  4. European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237-64.

  5. Baratta F, Pastori D, Del Ben M, Polimeni L, Labbadia G, Di Santo S, Piemonte F, et al. Reduced lysosomal acid lipase activity in adult patients with non-alcoholic fatty liver disease. EBioMedicine 2015; 2: 750-4.

  6. Hůlková H, Elleder M. Distinctive histopathological features that support a diagnosis of cholesterol ester storage disease in liver biopsy specimens. Histopathology 2012; 60: 1107-13.

  7. Boldrini R, Devito R, Biselli R, Filocamo M, Bosman C. Wolman disease and cholesteryl ester storage disease diagnosed by histological and ultrastructural examination of intestinal and liver biopsy. Pathol Res Pract 2004; 200: 231-40.

  8. Tovoli F, Napoli L, Negrini G, DÁddato S, Tozzi G, D’Amico J, Piscaglia F, et al. A relative deficiency of lysosomal acid lipase activity characterizes non-alcoholic fatty liver disease. Int J Mol Sci 2017; 18: E1134.

  9. Baratta F, Pastori D, Polimeni L, Tozzi G, Violi F, Angelico F, Del Ben M. Does lysosomial acid lipase reduction play a role in adult non-alcoholic fatty liver disease? Int J Mol Sci 2015; 16: 28014-21.

  10. Vespasiani-Gentilucci U, Gallo P, Piemonte F, Riva E, Porcari A, Vorini F, Tozzi G, et al. Lysosomal acid lipase activity is reduced both in cryptogenic cirrhosis and in cirrhosis of known etiology. PLOS ONE 2016; 11: e0156113.

  11. Angelico F, Corradini SG, Pastori D, Fargion S, Fracanzani AL, Angelico M, Bolondi L, et al. Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. Atherosclerosis 2017; 262: 179-84.

  12. Fouchier SW, Defesche JC. Lysosomal acid lipase A and the hypercholesterolaemic phenotype. Curr Opin Lipiodol 2013; 24: 332-8.

  13. Shteyer E, Villenchik R, Mahamid M, Nator N, Safadi R. Low serum lysosomal acid lipase activity correlates with advanced liver disease. Int J Mol Sci 2016; 17: 312.

  14. Selvakumar PK, Kabbany MN, Lopez R, Tozzi G, Alisi A, Alkhouri N, Nobili V. Reduced lysosomal acid lipase activity – A potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients. Dig Liver Dis 2016; 48: 909- 13.

  15. Hamilton J, Jones I, Srivastava R, Galloway P. A simple screening method for the measurement of lysosomal acid lípase using dried blood spots. Arch Dis Child 2013; 98: A40.

  16. Hoyumpa AM Jr, Greene HL, Dunn GD, Schenker S. Fatty liver: biochemical and clinical considerations. Am J Dig Dis 1975; 20: 1142-70.

  17. Ceci R, Francescon P, Mucci J, Cancelarich LN, Fossati CA, Rozenfeld PA. Reliability of enzyme assays in dried blood spots for diagnosis of 4 lysosomal storage disorders. Advances in Biological Chemistry 2011; 1: 58-64.

  18. Vespasiani-Gentilucci U, D’Amico J, De Vicentis A, Tozzi G, Vorini F, Gallo P, Carotti S, et al. Platelet count may impact on lysosomal acid lipase activity determination in dried blood spot. Clin Biochem 2017; 50: 726-8.

  19. Bentfled-Barker ME, Bainton DF. Identification of primary lysosomes in human megakaryocytes and platelets. Blood 1982; 59: 472-81.

  20. Muntoni S, Wiebusch H, Jansen-Rust M, Rust S, Schulte H, Berger K, Pisciotta L, et al. Heterozygosity for lysosomal acid lipase E8SJM mutation and serum lipid concentrations. Nut Metab Cardiovasc Dis 2013; 23: 732-6.

  21. Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, Tanaka K, et al. Autophagy regulates lipid metabolism. Nature 2009; 458: 1131-5.

  22. Puri P, Baillie RA, Wiest MM, Mirshani F, Choudhury J, Cheung O, Sargeant C, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46: 1081-90.

  23. Zhang QQ, Lu LG. Nonalcoholic fatty liver disease: Dyslipidemia, risk for cardiovascular complications, and treatment strategy. J Clin Transl Hepatol 2015; 3: 78-84.

  24. Melhem A, Muhanna N, Bishara A, Alvarez CE, Ilan Y, Bishara T, Horani A, et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 2006; 45: 60-71.

  25. Gur C, Doron S, Kfir-Erenfeld S, Horwitz E, Abu-Tair L, Safadi R, Mandelboim O. NKp46-mediated killing of human and mouse hepatic stellate cells attenuates liver fibrosis. Gut 2012; 61: 885-93.

  26. Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J Endocrinol 2013; 218: R25-36.

  27. Scott SA, Liu B, Nazarenko I, Martis S, Kozlitina J, Yang Y, Ramirez C, et al. Frequency of the cholesteryl ester storage disease common LIPA E8SJM mutation (c.894G>A) in various racial and ethnic groups. Hepatology 2013; 58: 958-65.

  28. Lohse P, Maas S, Lohse P, Elleder M, Kirk JM, Besley GT, Seidel D. Compound heterozygosity for a Wolman mutation is frequent among patients with cholesteryl ester storage disease. J Lipid Res 2000; 41: 23-31.




2020     |     www.medigraphic.com